
Apogee Therapeutics, Inc.
APGE
Since 2022
Headquarters:
Exchange:
Industry:
Number of Employees:
Current Fiscal Year:
Market Cap:
Price per Share:
Quarterly Dividend per Share:
Price History
Latest Prices
Date | Open | High | Low | Close |
---|---|---|---|---|
2025-08-01 | 37.6 | 38.25 | 36.5601 | 37.75 |
2025-07-31 | 37.3 | 38.54 | 37.29 | 38.26 |
2025-07-30 | 38.035 | 38.31 | 36.82 | 37.61 |
2025-07-29 | 39.86 | 39.86 | 37.465 | 37.93 |
2025-07-28 | 40.78 | 40.9 | 38.75 | 39.66 |
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.